These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
2267 related items for PubMed ID: 18261327
1. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients]. Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL. Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327 [Abstract] [Full Text] [Related]
2. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy. Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX. Chin Med J (Engl); 2006 Oct 20; 119(20):1677-82. PubMed ID: 17097013 [Abstract] [Full Text] [Related]
3. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study. Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS. Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166 [Abstract] [Full Text] [Related]
4. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM. Antivir Ther; 2004 Apr 20; 9(2):197-204. PubMed ID: 15134181 [Abstract] [Full Text] [Related]
5. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers. Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. Scand J Immunol; 2008 Dec 20; 68(6):652-60. PubMed ID: 19055701 [Abstract] [Full Text] [Related]
6. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F. HIV Med; 2006 Oct 20; 7(7):431-6. PubMed ID: 16925728 [Abstract] [Full Text] [Related]
7. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A. Antivir Ther; 2005 Oct 20; 10(5):605-14. PubMed ID: 16152754 [Abstract] [Full Text] [Related]
8. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection. Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T. Clin Ther; 1999 Nov 20; 21(11):1853-63. PubMed ID: 10890257 [Abstract] [Full Text] [Related]
9. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients. Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, Liu C. Intervirology; 2010 Nov 20; 53(4):240-6. PubMed ID: 20357493 [Abstract] [Full Text] [Related]
10. [The evaluation of four-year highly active antiretroviral therapy in HIV-1 infected patients]. Deng XJ, He Y, Yang L, Zou SP, Yang H, Zheng YH. Zhonghua Nei Ke Za Zhi; 2011 Mar 20; 50(3):230-4. PubMed ID: 21600088 [Abstract] [Full Text] [Related]
11. Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease. Lepej SZ, Begovac J, Vince A. FEMS Immunol Med Microbiol; 2006 Apr 20; 46(3):351-9. PubMed ID: 16553807 [Abstract] [Full Text] [Related]
12. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Moore RD, Keruly JC. Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456 [Abstract] [Full Text] [Related]
13. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients. Almeida M, Cordero M, Almeida J, Orfao A. Cytometry B Clin Cytom; 2007 Jan 15; 72(1):22-33. PubMed ID: 17051525 [Abstract] [Full Text] [Related]
14. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy. Stone SF, Price P, French MA. HIV Med; 2005 Jul 15; 6(4):278-83. PubMed ID: 16011533 [Abstract] [Full Text] [Related]
15. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S. Pediatrics; 2007 Oct 15; 120(4):e856-61. PubMed ID: 17846147 [Abstract] [Full Text] [Related]
16. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years. Zhou HY, Zheng YH, Zhang CY, Chen J, He Y, Ding PP, Li H. Viral Immunol; 2007 Oct 15; 20(1):180-7. PubMed ID: 17425432 [Abstract] [Full Text] [Related]
17. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). HIV Med; 2005 May 15; 6(3):198-205. PubMed ID: 15876287 [Abstract] [Full Text] [Related]
18. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM. AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217 [Abstract] [Full Text] [Related]
19. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART. Choremi-Papadopoulou H, Tsalimalma K, Dafni U, Dimitracopoulou A, Kordossis T. J Med Virol; 2004 Jun 20; 73(2):235-43. PubMed ID: 15122798 [Abstract] [Full Text] [Related]
20. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI. Cytometry B Clin Cytom; 2007 Jan 15; 72(1):14-21. PubMed ID: 17041945 [Abstract] [Full Text] [Related] Page: [Next] [New Search]